Claudia Pauligk
Overview
Explore the profile of Claudia Pauligk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheck M, Goetze T, Ettrich T, Schmalenberg H, Clemens M, Mahlberg R, et al.
Oncol Res Treat
. 2024 Sep;
47(11):549-560.
PMID: 39250905
Introduction: In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line...
2.
Goetze T, Reichart A, Bankstahl U, Pauligk C, Loose M, Kraus T, et al.
Ann Surg Oncol
. 2024 Mar;
31(6):4073-4083.
PMID: 38459418
Background: Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer....
3.
Masetti M, Al-Batran S, Goetze T, Thuss-Patience P, Riera Knorrenschild J, Goekkurt E, et al.
Int J Cancer
. 2024 Mar;
154(12):2142-2150.
PMID: 38447003
FOLFOX plus nivolumab represents a standard of care for first-line therapy of advanced gastroesophageal cancer (aGEC) with positive PD-L1 expression. The efficacy of second-line VEGFR-2 inhibition with ramucirumab (RAM) plus...
4.
Lorenzen S, Gotze T, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al.
J Clin Oncol
. 2023 Nov;
42(4):410-420.
PMID: 37963317
Purpose: This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a perioperative treatment for patients with resectable esophagogastric adenocarcinoma...
5.
Hess T, Maj C, Gehlen J, Borisov O, Haas S, Gockel I, et al.
EBioMedicine
. 2023 Jul;
94:104709.
PMID: 37480624
No abstract available.
6.
Goetze T, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, et al.
Int J Cancer
. 2023 Jul;
153(10):1726-1733.
PMID: 37455496
Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS-102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter,...
7.
Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Riera Knorrenschild J, et al.
BMC Cancer
. 2023 Jun;
23(1):561.
PMID: 37337155
Background: Paclitaxel in combination with ramucirumab is the standard of care second-line therapy in gastro-esophageal adenocarcinoma (GEA). As the number of taxane pretreated patients in the perioperative or first-line setting...
8.
Hess T, Maj C, Gehlen J, Borisov O, Haas S, Gockel I, et al.
EBioMedicine
. 2023 May;
92:104616.
PMID: 37209533
Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim...
9.
Goetze T, Hofheinz R, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, et al.
Int J Cancer
. 2023 Mar;
153(1):153-163.
PMID: 36883420
This multicenter, randomized phase II/III study evaluated the addition of the vascular endothelial growth factor receptor-2 inhibitor ramucirumab to FLOT as perioperative treatment for resectable esophagogastric adenocarcinoma. Patients received either...
10.
Hofheinz R, Merx K, Haag G, Springfeld C, Ettrich T, Borchert K, et al.
J Clin Oncol
. 2022 Jun;
40(32):3750-3761.
PMID: 35709415
Purpose: High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab...